Vaccine and Phylogeny Studies Of Simian Immunodeficiency Virus (SIV)

Niaid Extramural Activities

Investigators

Linked publications & trials

Abstract

VACCINE STUDIES:[unreadable] A crucial element in the development of effective prophylactic strategies for AIDS is an experimental animal model in which the course of immunodeficiency virus infection parallels the pathogenesis of the human disease. SIV infection of macaques is a relevant model since it induces an immunodeficiency syndrome in infected macaques that is remarkably similar to human AIDS. Recent studies suggest that SIV-infection is likely to be more representative of human AIDS pathogenesis than SHIV viruses that utilize CXCR4 as their coreceptor and target naive rather than memory CD4+ T cells. During primary viremia in SHIV-infected macaques, massive elimination of CXCR4 naive CD4+ T cells occurred. In contrast, CCR5+ memory CD4+ T cells were selectively depleted in rapidly progressing SIV-infected macaques. Thus SHIV and SIV target different subsets of CD4+ T cells. These differences explain the different pathogenesis of SIV and SHIV. Importantly, in the context of developing an effective vaccine, regimens that suppress SHIV might not protect monkeys against SIV or humans against HIV.[unreadable] [unreadable] The early major vaccine effort within my laboratory has been the evaluation of the highly attenuated vaccinia virus Ankara (MVA) strain as a recombinant vector. We used MVA-SIV recombinants expressing Env, Gag-pol or both in three separate challenge studies in rhesus macaques. Macaques expressing the MamuA*01 MHC-Class I allele were used to evaluate cellular immune responses. Immunization with MVA-SIV recombinants resulted in a reduction in setpoint plasma viral load that was associated with prolonged survival. These data demonstrate that vaccination with MVA-SIV recombinants results in significant protection from high viremia and AIDS. These animals have been the focus of follow-up studies to determine the long-term efficacy of such vaccines. All but two vaccinees have progressed to AIDS by seven years after challenge suggesting that immune escape from such vaccines is a major concern. [unreadable] [unreadable] All of our previous vaccine studies have used SIVsmH4 as an immunogen, which is a lab adapted envelope that does not generate antibodies that cross-neutralize our SIVsmE660 challenge virus. These studies have focused mostly on generating cellular immune responses. The purpose of future experiments will be to focus on generating antibody that will neutralize the pathogenic SIVsmE543 and study the role of this antibody in the SIV model. Prior studies have only demonstrated a role for neutralizing antibody in vivo using the less pathogenic SIVmne model or in SHIV. Similar studies using SIVmac239 have been hampered due to the neutralization resistance associated with its envelope glycoprotein. We therefore generated a MVA recombinant that expresses the less neutralization-resistant SIVsmE543-3 envelope and a plasmid of the codon-optimized gp140 which has been used to generate recombinant trimeric SIVsmE543-3 envelope. [unreadable] [unreadable] A non-integrating mutant, SIVsmD116N clone, was derived from SIVsmE543-3 by introducing an Asp (D) to Asn (N) mutation into the invariant D-116 integrase residue in the catalytic domain. This point mutation completely abolishes viral DNA integration of HIV without affecting other known viral functions such as reverse transcription and nuclear targeting. The SIVsmD116N and wild type SIVsmE543-3 clones were transfected into 293T cells to generate cell free virus and their replication was assessed in CEMx174 cells, macaque PBMC and macaque monocyte-derived macrophages (MDM). While the wild type virus replicated in each of these cell types, no RT activity was observed in cell-free media following infection with the integrase mutant. Alu-PCR confirmed that SIVsmD116N did not integrate into genomic DNA. The SIVsmD116N mutant was able to synthesize viral DNA with almost equal efficiency to wild type virus and viral DNA persisted in macrophages for as long as 30 days. The capacity of a nonintegrating SIV to persistently generate viral products suggests that nonintegrating lentiviral vectors could serve to express protein for vaccine purposes, without the permanency of an integrated retrovirus or disruption of normal cellular genes.[unreadable] [unreadable] PHYLOGENY OF SIV/HIV:[unreadable] The human immunodeficiency viruses, HIV-1 and HIV-2, are members of a large family of primate lentiviruses that have their origins in African primates. Each of the human viruses arose following cross-species transmission from a naturally-infected primate to humans SIVsm from sooty mangabey monkeys for HIV-2 and SIVcpz from chimpanzees for HIV-1. The goal of this project has been to molecularly characterize novel SIV isolates from wild-caught African monkeys as well as to study the evolution of virus in SIV-infected macaques. We initiated these studies by characterizing SIV from a sooty mangabey (SIVsm), SIV from three of the species of African green monkeys (vervets, grivets and tantalus), SIV from Sykes monkeys and SIV from L'Hoest monkeys (C. lhoesti) and more recently characterized SIVrcm from a wild caught redcapped mangabey from Nigeria and SIVmnd-2 and SIVdrl. [unreadable] [unreadable] The evolution of SIV in the cerebral spinal fluid (CSF) was compared with the virus that evolved in the plasma of two rhesus macaques which developed SIV encephalitis. While the virus in the CSF and plasma were similar during primary infection, distinct substitutions were observed sequentially in the two compartments. These findings are consistent with compartmentalization between the brain and blood during development of neuro-AIDS and the evolution of viruses with distinct genotypes and potentially distinct biological phenotypes in the brain.